My IDSA Contact Us
IDSA NewsPrint-Friendly Newsletter
Forward to a Friend
Search Back Issues
Education & Training Resources Practice Guidelines Journals & Publications Policy & Advocacy Meetings About IDSA
July 2017
Promoting the Value of ID For All Who Work in Our Field
William G. Powderly, MD, FIDSA
IDSA President

We are hard at work analyzing the data collected from our 2017 Compensation Survey. I’m pleased to report that we reached our goal of 2,500 participants in this survey, making it the largest survey of its kind and the most accurate source for ID physician compensation data. This larger sample size will enable us to make comparisons across focus areas within the field such as pediatrics, research, clinical practice, public health and industry and across geographic differences and age differences. It is our hope that it will also provide us with insight into the pay disparity across gender identified in our 2015 survey.

IDSA, AASLD Express Strong Concerns over Cochrane Review of Hep C Drugs

A recent review of drugs used to treat hepatitis C by the Cochrane Group drew a heated response from IDSA and AASLD who partner in, an online resource providing guidance in the treatment of the virus. The groups submitted a letter to the Cochrane editors outlining their concerns and calling for the revision or withdrawal of the review. The groups also detailed their objections to the review in commentaries published in their respective journals. 

HIVMA Members Active in Stopping an ACA Repeal
Having fallen short of securing the votes needed to pass the Better Care Reconciliation Act, the Senate is expected to vote early the week of July 24 on a bill that will repeal key parts of the Affordable Care Act, including the Medicaid Expansion, premium tax credits, and cost sharing subsidies, without a replacement plan. HIVMA has been active in opposing replace and repeal efforts on several fronts.
NIH Rethinks Next Generation Researchers Initiative
The National Institutes of Health has announced that it will abandon the implementation of its controversial Grant Support Index at this time based on feedback from an advisory council, IDSA, and other stakeholders. Instead, the agency will create a special fund, to be called the Next Generation Researchers Initiative, for early- and mid-career investigators to increase support for researchers with less than 10 years’ experience as an NIH-funded principal investigator. 
Journal Club
  • Ultra-Short-Course Antibiotics in Patients with Suspected VAP: A Strategy to Reduce Overuse?
  • Shedding Light on HBcAb+ Patients by Studying Stem Cell Transplant Recipients
  • Addition of MRSA Coverage for Nonculturable Cellulitis Provides No Benefit
  • Effect of ART and Depressive Symptoms on Mortality in HIV-Infected Women
  • Streptococcal Prosthetic Joint Infection with Implant Retention: “Not So Good” Outcomes and Role for Rifampin
  • In Septic Patients, Delayed Second Dose of Antibiotics Is Common, Associated with Adverse Effects
Upcoming dates to remember

The combined meeting of IDSA, SHEA, HIVMA, and PIDS, Oct. 4-8 in San Diego, CA. See you there!

Improved Online Search Functionality for IDSA’s Guidelines
IDSA Members Appointed to CMS MACRA Subcommittees
Former Georgia Health Commissioner Named New Head of CDC
Federal Funding News for Fiscal Year 2018
Become a Better Advocate
Science Speaks Highlights Trump Administration PEPFAR Plans
Opportunities to Recognize Leaders in Global Health
IDWeek 2017 is Fast Approaching
ABIM to Discontinue Knowledge Modules after 2017-18 Release
IDSA Foundation Announces Medical Scholarship Recipients
What’s Your Pick? Drafting Favorite Antibiotics in the Latest OFID Podcast
Webinar Series on Molecular Diagnostics
Promoting the Value of ID For All Who Work in Our Field
IDSA, AASLD Express Strong Concerns over Cochrane Review of Hep C Drugs
HIVMA Members Active in Stopping an ACA Repeal
NIH Rethinks Next Generation Researchers Initiative
Journal Club
IDSA | 1300 Wilson Blvd., Suite 300 | Arlington, VA 22209 | Phone: (703) 299-0200
To ensure delivery, please add '' to your email address book or Safe Sender List.
If you are still having problems receiving our communications,
see our white-listing page for more details.

Unsubscribe here